Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.

Oncotarget - 31 May 2016

Inoue Yusuke, Yoshimura Katsuhiro, Mori Kazutaka, Kurabe Nobuya, Kahyo Tomoaki, Mori Hiroki, Kawase Akikazu, Tanahashi Masayuki, Ogawa Hiroshi, Inui Naoki, Funai Kazuhito, Shinmura Kazuya, Niwa Hiroshi, Suda Takafumi, Sugimura Haruhiko

Abstract excerpt

New reliable biomarkers are needed to predict the response to immune checkpoint inhibitors against programmed death-1 (PD-1) and its ligand (PD-L1), because PD-L1 expression on tumor cells has limited power for selecting patients who may benefit from such therapy. Here we investigated the significance of PD-L1 and PD-L2 gene copy number gains using fluorescence in situ hybridization as well as PD-L1 and PD-L2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Amplification

Share to Janus Kinase 2

Share to Kaplan-Meier Estimate

Share to Lymphatic Metastasis

Share to Pneumonectomy

Share to Proportional Hazards Models

Source

Open in PubMed Open full text

Identifiers

PMID: 27050074
DOI: 10.18632/oncotarget.8528
PMCID: PMC5078001

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.PMID 27050074Read ↗

PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapySemantic proximity Read ↗

Primary pulmonary lymphoepithelioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden.Semantic proximity Read ↗

Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancerSemantic proximity Read ↗

CD 274 ( PDL 1) and JAK 2 genomic amplifications in pulmonary squamous‐cell and adenocarcinoma patientsSemantic proximity Read ↗

PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung.Semantic proximity Read ↗

Impact of copy number variant and single nucleotide polymorphism of the programmed death‑ligand 1 gene, programmed death‑ligand 1 protein expression and therapy regimens on overall survival in a large group of Caucasian patients with non‑small cell lung carcinomaSemantic proximity Read ↗

Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer.Semantic proximity Read ↗

Significance of programmed death-ligand 1 expression in resected lung cancer and its relationship with EGFR mutation.Semantic proximity Read ↗

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.Semantic proximity Read ↗

Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas.Semantic proximity Read ↗

Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy.Semantic proximity Read ↗

Significance of EGFR signaling pathway genetic alterations in radically resected non-small cell lung cancers from a Polish cohort. One institutional study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.